MX2009003761A - Derivados biciclicos y triciclicos como antagonistas del receptor de trombina. - Google Patents

Derivados biciclicos y triciclicos como antagonistas del receptor de trombina.

Info

Publication number
MX2009003761A
MX2009003761A MX2009003761A MX2009003761A MX2009003761A MX 2009003761 A MX2009003761 A MX 2009003761A MX 2009003761 A MX2009003761 A MX 2009003761A MX 2009003761 A MX2009003761 A MX 2009003761A MX 2009003761 A MX2009003761 A MX 2009003761A
Authority
MX
Mexico
Prior art keywords
sup
bond
bicyclic
receptor antagonists
thrombin receptor
Prior art date
Application number
MX2009003761A
Other languages
English (en)
Inventor
Yan Xia
Samuel Chackalamannil
Mariappan V Chelliah
Yuguguang Wang
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MX2009003761A publication Critical patent/MX2009003761A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)

Abstract

Los tricíclicos heterocíclicos-sustituidos de la fórmula (I): (ver fórmula (I)) o una sal o solvato farmacéuticamente aceptable de dicho compuesto, isómero o mezcla racémica, en donde representa un enlace doble opcional, la línea punteada es opcionalmente un enlace o no es un enlace, dando como resultado un enlace doble o un enlace sencillo, según lo permita el requerimiento de valencia y en donde E, A, G, M Het, B, X, R3, R10, R11, R32 y R33 son como se definen en la presente y los sustituyentes restantes son como se definen en la especificación, así como composiciones farmacéuticas que los contienen y un método para el tratamiento de enfermedades asociadas con trombosis, aterosclerosis, restenosis, hipertensión, angina de pecho, arritmia, paro cardíaco, cáncer, con la administración de dichos compuestos; también se reclama la terapia de combinación con otros agentes cardiovasculares.
MX2009003761A 2006-10-04 2007-10-02 Derivados biciclicos y triciclicos como antagonistas del receptor de trombina. MX2009003761A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84935406P 2006-10-04 2006-10-04
PCT/US2007/021277 WO2008042422A2 (en) 2006-10-04 2007-10-02 Bicyclic and tricyclic derivatives as thrombin receptor antagonists

Publications (1)

Publication Number Publication Date
MX2009003761A true MX2009003761A (es) 2009-06-30

Family

ID=39269039

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009003761A MX2009003761A (es) 2006-10-04 2007-10-02 Derivados biciclicos y triciclicos como antagonistas del receptor de trombina.

Country Status (13)

Country Link
US (2) US8153664B2 (es)
EP (1) EP2069326B1 (es)
JP (1) JP2010505842A (es)
KR (1) KR20090074219A (es)
CN (1) CN101541782A (es)
AR (1) AR063123A1 (es)
AU (1) AU2007305269A1 (es)
CA (1) CA2667082A1 (es)
IL (1) IL198009A0 (es)
MX (1) MX2009003761A (es)
TW (1) TW200823205A (es)
WO (1) WO2008042422A2 (es)
ZA (1) ZA200902362B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8227412B2 (en) * 2007-03-29 2012-07-24 Tsopanoglou Nikos E Bioactive parstatin peptides and methods of use
WO2009071661A1 (en) * 2007-12-07 2009-06-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment and diagnosis of bone mineral density related diseases
WO2010141525A1 (en) * 2009-06-04 2010-12-09 Schering Corporation Active metabolite of a thrombin receptor antagonist
NZ731621A (en) 2009-12-04 2019-01-25 Sunovion Pharmaceuticals Inc Multicyclic compounds and methods of use thereof
ES2527535T3 (es) 2010-04-16 2015-01-26 Sanofi Piridil-vinil-pirazolo-quinolinas como inhibidores de PAR1
WO2011128421A1 (de) 2010-04-16 2011-10-20 Sanofi Trizyklische pyridyl-vinyl-pyrrole als par1-inhibitoren
US9340530B2 (en) 2012-03-06 2016-05-17 Merck Sharp & Dohme Corp. Preparation and use of bicyclic himbacine derivatives as PAR-1 receptor antagonists
EP3035930A4 (en) 2013-08-22 2017-03-08 Merck Sharp & Dohme Corp. 7a-heterocycle substituted- 6, 6-difluoro bicyclic himbacine derivatives
WO2015026693A1 (en) 2013-08-22 2015-02-26 Merck Sharp & Dohme Corp. 7a-amide substituted-6,6-difluoro bicyclic himbacine derivatives
EP3035928B1 (en) 2013-08-22 2023-10-18 Merck Sharp & Dohme LLC 3'-pyridyl substituted- 6,6-difluoro bicyclic himbacine derivatives
WO2016060940A1 (en) * 2014-10-15 2016-04-21 Merck Sharp & Dohme Corp. Preparation and use of cyclic sulfonamide derivatives as par-1 receptor antagonists
WO2016058144A1 (en) * 2014-10-15 2016-04-21 Merck Sharp & Dohme Corp. Preparation and use of cyclic sulfonamide derivatives as par-1 receptor antagonists
CN105985303B (zh) * 2015-02-13 2020-08-14 上海彩迩文生化科技有限公司 抗凝血剂的制备方法、中间体及其制备方法
CN105732595B (zh) 2015-12-22 2018-08-28 山东大学 基于萜类衍生物的par-1抑制剂及其制备方法和在治疗血栓性疾病中的用途
CN107129477A (zh) * 2016-02-26 2017-09-05 上海星泰医药科技有限公司 ((1R,3aR,4aR,6R,8aR,9S,9aR)-9-甲酰基-1-甲基-3-氧杂十二氢萘[2,3-c]-6-呋喃基)羧酸乙酯的制备方法
KR20190065246A (ko) 2016-07-29 2019-06-11 선오비온 파마슈티컬스 인코포레이티드 화합물 및 조성물 및 이들의 용도
IL264446B1 (en) 2016-07-29 2024-05-01 Pgi Drug Discovery Llc Compounds and compositions and their use
IL268694B2 (en) 2017-02-16 2023-10-01 Sunovion Pharmaceuticals Inc Treatment of schizophrenia
EP3661929B1 (en) 2017-08-02 2021-07-14 Sunovion Pharmaceuticals Inc. Isochroman compounds and uses thereof
WO2019161238A1 (en) 2018-02-16 2019-08-22 Sunovion Pharmaceuticals Inc. Salts, crystal forms, and production methods thereof
CN110559294A (zh) * 2018-06-06 2019-12-13 杨仑 脂肪性肝病及其相关疾病的预防和治疗性药物
AU2020236225A1 (en) 2019-03-14 2021-09-16 Sunovion Pharmaceuticals Inc. Salts of a isochromanyl compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof
CN110627710B (zh) * 2019-09-29 2020-06-05 山东大学 一种新型par-1抑制剂及其制备方法和在预防和/或治疗血栓性疾病中的用途
US11738002B2 (en) 2020-04-14 2023-08-29 Sunovion Pharmaceuticals Inc. Methods of treating neurological and psychiatric disorders
CN112759548B (zh) * 2020-12-31 2021-11-02 山东大学 一种par-1抑制剂及其制备方法
CN115043820B (zh) * 2022-05-27 2024-03-22 山东大学 Par-1抑制剂及其类似物的制备方法和在血栓性疾病防治中的应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1201061A (en) * 1966-08-26 1970-08-05 Endo Lab Oxo pyrroles and process for preparing same
IL106197A (en) 1992-07-30 1999-11-30 Cor Therapeutics Inc Agagonists for the rhombin receptors and pharmaceutical preparations containing them
US5874382A (en) * 1996-11-13 1999-02-23 E. I. Du Pont De Nemours And Company Cyclic sulfonamide herbicides
US20030185830A1 (en) * 1997-02-25 2003-10-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6063847A (en) * 1997-11-25 2000-05-16 Schering Corporation Thrombin receptor antagonists
PE133799A1 (es) 1997-11-25 2000-01-10 Schering Corp Antagonistas del receptor de trombina
FR2807040B1 (fr) * 2000-03-31 2002-05-17 Oreal Procede de preparation de composes 3-(4-hydroxy-1h-indol-5- ylmethyl)-pyridiniums utilisant une reaction d'aldolisation
CA2410177C (en) * 2000-06-15 2010-05-11 Schering Corporation Thrombin receptor antagonists
US20040192753A1 (en) * 2000-06-15 2004-09-30 Samuel Chackalamannil Methods of use of thrombin receptor antagonists
US7488742B2 (en) * 2000-06-15 2009-02-10 Schering Corporation Thrombin receptor antagonists
MXPA04003610A (es) * 2001-10-18 2004-07-27 Schering Corp Analogos de himbacina como antagonistas del receptor de trombina.
JP2003183278A (ja) * 2001-12-25 2003-07-03 Sagami Chem Res Center 芳香族複素環を有するヒンバシン類縁体
ATE378330T1 (de) 2002-04-16 2007-11-15 Schering Corp Trizyklische thrombin rezeptor antagonisten
CA2572750A1 (en) * 2003-09-10 2005-03-17 Anil Koul Heterobicyclic compounds as pharmaceutically active agents
EA010488B1 (ru) * 2003-12-05 2008-10-30 Янссен Фармацевтика Н.В. 6-замещённые 2-хинолиноны и 2-хиноксалиноны как ингибиторы поли (адф-рибоза) полимеразы
JP2008500998A (ja) * 2004-05-28 2008-01-17 シュペーデル・エクスペリメンタ・アーゲー 複素環式化合物およびアルドステロンシンターゼ阻害薬としてのそれらの使用
US7429666B2 (en) * 2004-06-10 2008-09-30 Merck Frosst Canada Ltd. Pyridine analogs as C5a antagonists
CN100581837C (zh) * 2004-07-29 2010-01-20 株式会社艾迪科 光学记录材料和光学记录介质
KR20070060156A (ko) * 2004-10-04 2007-06-12 미리어드 제네틱스, 인크. 알츠하이머병 치료용 화합물
WO2006041872A2 (en) 2004-10-08 2006-04-20 Schering Corporation Thrombin receptor antagonists
JP4705367B2 (ja) * 2004-12-24 2011-06-22 花王株式会社 染毛剤組成物
RU2007143049A (ru) * 2005-04-21 2009-05-27 Ниппон Синяку Ко., Лтд. (Jp) Производное фталазинона и содержащая его фармацевтическая композиция
DE102005049953A1 (de) * 2005-10-19 2007-04-26 Sanofi-Aventis Deutschland Gmbh Carbamoylbenzotriazol-derivate als Inhibitoren von Lipasen und Phospholipasen
KR20080110886A (ko) * 2006-04-04 2008-12-19 미리어드 제네틱스, 인크. 질병 및 장애용 화합물
AU2007240450B2 (en) * 2006-04-21 2011-12-22 Eli Lilly And Company Cyclohexylimidazole lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
AR061664A1 (es) * 2006-06-29 2008-09-10 Schering Corp Derivados de himbacina como antagonistas del receptor de trombina biciclicos y triciclicos sustituidos. composiciones farmaceuticas.
AU2007334436A1 (en) * 2006-12-15 2008-06-26 Abbott Laboratories Novel oxadiazole compounds

Also Published As

Publication number Publication date
IL198009A0 (en) 2009-12-24
WO2008042422A3 (en) 2009-03-26
TW200823205A (en) 2008-06-01
AU2007305269A1 (en) 2008-04-10
CN101541782A (zh) 2009-09-23
AR063123A1 (es) 2008-12-30
EP2069326A2 (en) 2009-06-17
JP2010505842A (ja) 2010-02-25
US20080090830A1 (en) 2008-04-17
KR20090074219A (ko) 2009-07-06
US8153664B2 (en) 2012-04-10
CA2667082A1 (en) 2008-04-10
EP2069326B1 (en) 2015-03-18
WO2008042422A2 (en) 2008-04-10
ZA200902362B (en) 2010-10-27
US20120157403A1 (en) 2012-06-21

Similar Documents

Publication Publication Date Title
MX2009003761A (es) Derivados biciclicos y triciclicos como antagonistas del receptor de trombina.
TW200626584A (en) Thrombin receptor antagonists
WO2006105217A3 (en) Spirocyclic thrombin receptor antagonists
SG164279A1 (en) Tricyclic thrombin receptor antagonists
WO2007075809A3 (en) Oxazoloisoquinoline derivatives as thrombin receptor antagonists
WO2007126771A3 (en) Monocyclic and bicyclic himbacine derivatives useful as thrombin receptor antagonists
EA200801909A1 (ru) Соединения пиридина для лечения заболеваний, опосредованных действием простагландина
MY139335A (en) Substituted tricyclic himbacine derivatives that are useful as thrombin receptor antagonists
EA201000615A1 (ru) Производные имидазо[1,2-а]пиридина, применимые в качестве ингибиторов апк (активиноподобной киназы)
TW200635897A (en) Piperidine derivatives and their use as anti-inflammatory agents
NO20072978L (no) Nye betuinderivater, preparat derav og anvendelse derav
WO2008115098A3 (fr) 2,3,4,5-tétrahydro-1h-pyrido[4,3-b]indoles substitués ainsi que procédés de leur fabrication et leur utilisation
MX2009003758A (es) Antagonistas del receptor de trombina basados en la unidad triciclica modificada de himbacina.
WO2009065919A3 (de) Organische verbindungen
BRPI0510560A (pt) pirido[2,3-d] pirimidin-7-onas pirrolil substituìdas e seus derivados como agentes terapêuticos
TW200728307A (en) Novel spirochromanone derivatives
DE602005021150D1 (de) 3-substituierte pyridinderivate als h3-antagonisten
GEP20094638B (en) Benzimidazolone carboxylic acid derivatives
NO20071137L (no) Nye piperidinderivater for behandling av depresjon
WO2009065922A3 (de) Organische verbindungen
GB0507601D0 (en) Compounds
ATE399156T1 (de) Neue indol- oder benzimidazol-derivate
WO2007120730A3 (en) Fused ring thrombin receptor antagonists
TW200606153A (en) Process for producing pyridine derivatives of Nk-1 receptor antagonist
NO20080671L (no) Bisykliske piperaziner som metabotrofiske glutamatreseptorantagonister

Legal Events

Date Code Title Description
FA Abandonment or withdrawal